Abstract
Nanotechnology is a rapidly emerging drug-delivery system that makes possible the controlled release of small molecules, and nanodelivery of therapeutic molecules using nanoparticles or nanogels represents a major improvement for more focused delivery of such therapeutic molecules. The delivery of insulin for the control of diabetes mellitus (DM) and aldose reductase inhibitor (ARI) for diabetic complications may provide better treatment of diabetes. A structural overview of aldose reductase including computational docking experiments with HAR-1, various ARIs, aldose-keto reductase, and nanodelivery of insulin, ARI's, and drug molecules are described.
Keywords: Aldose reductase, aldose reductase inhibitors, aldo-keto reductase, diabetes, insulin, nanodelivery, nanogels, tricyclic pyrone molecules, sorbitol, dehydrogenase, nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate, glutathione reductase, glycation, nasal, rectal, pulmonary, microparticles, pre-clinical
Mini-Reviews in Medicinal Chemistry
Title:Aldose Reductase Inhibitors and Nanodelivery of Diabetic Therapeutics
Volume: 12 Issue: 4
Author(s): A. M. Prior, M. Thapa, D. H. Hua
Affiliation:
Keywords: Aldose reductase, aldose reductase inhibitors, aldo-keto reductase, diabetes, insulin, nanodelivery, nanogels, tricyclic pyrone molecules, sorbitol, dehydrogenase, nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate, glutathione reductase, glycation, nasal, rectal, pulmonary, microparticles, pre-clinical
Abstract: Nanotechnology is a rapidly emerging drug-delivery system that makes possible the controlled release of small molecules, and nanodelivery of therapeutic molecules using nanoparticles or nanogels represents a major improvement for more focused delivery of such therapeutic molecules. The delivery of insulin for the control of diabetes mellitus (DM) and aldose reductase inhibitor (ARI) for diabetic complications may provide better treatment of diabetes. A structural overview of aldose reductase including computational docking experiments with HAR-1, various ARIs, aldose-keto reductase, and nanodelivery of insulin, ARI's, and drug molecules are described.
Export Options
About this article
Cite this article as:
A. M. Prior, M. Thapa, D. H. Hua , Aldose Reductase Inhibitors and Nanodelivery of Diabetic Therapeutics, Mini-Reviews in Medicinal Chemistry 2012; 12 (4) . https://dx.doi.org/10.2174/138955712799829294
DOI https://dx.doi.org/10.2174/138955712799829294 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunosuppressive Properties of Mesenchymal Stem Cells: Advances and Applications
Current Molecular Medicine Diabetic Retinopathy and Atherosclerosis: is there a Link?
Current Diabetes Reviews Meet the Editorial Board:
Current Topics in Medicinal Chemistry Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development
Current Diabetes Reviews The Role of Plant-Derived Compounds in Managing Diabetes Mellitus: A Review of Literature from 2014 To 2019
Current Medicinal Chemistry Editorial (Thematic Issue: Induced Cell-Based Transplantation to Therapeutically Target Spinal Cord Disorders)
Current Stem Cell Research & Therapy The Effect of Stress Management Program on Perceived Stress in Patients with Type 2 Diabetes: A Randomized Controlled Trial
Current Diabetes Reviews Review on Patents for Potent Anticoagulant Antithrombin-Heparin Covalent Complexes that Control Thrombosis In Vivo
Recent Patents on Biomedical Engineering (Discontinued) The Application of Freidinger Lactams and their Analogs in the Design of Conformationally Constrained Peptidomimetics
Current Medicinal Chemistry Cardiovascular Risk and Endothelial Dysfunction: The Preferential Route for Atherosclerosis
Current Pharmaceutical Biotechnology Leukocytes in Diabetic Retinopathy
Current Diabetes Reviews HMGB1-Directed Drug Discovery Targeting Cutaneous Inflammatory Dysregulation
Current Drug Metabolism Development of Neurotrophic Molecules for Treatment of Neurode-generation
Current Protein & Peptide Science Neurological Disorders in Medical Use of <i>Cannabis</i>: An Update
CNS & Neurological Disorders - Drug Targets Focus on the Role of Glutamate in the Pathology of the Peripheral Nervous System
CNS & Neurological Disorders - Drug Targets Editorial (Hot Topic: Network Biology: Towards Systematic Understanding of Biological Systems)
Current Bioinformatics Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry Diagnostic Tools, Biomarkers, and Treatments in Diabetic polyneuropathy and Cardiovascular Autonomic Neuropathy
Current Diabetes Reviews Preventive and Therapeutic Potentials of Anthocyanins in Diabetes and Associated Complications
Current Medicinal Chemistry Current Therapies and Emerging Targets for the Treatment of Diabetes
Current Pharmaceutical Design